Characteristics of patients with hypertension in a population with type 2 diabetes mellitus. Results from the Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Hypertension Study)

Sabuncu, Tevfik; Sönmez, Alper; Eren, Mehmet Ali; Şahin, İ̇brahim; Çorapçıoğlu, Demet; Üçler, Rıfkı; Akın, Şafak; Haymana, Cem; Demirci, İbrahim; Atmaca, Ayşegül; Ersöz, Halil Önder; Satman, İlhan; Bayram, Fahri

doi:10.1016/j.pcd.2020.11.001

Cited by 19 publications

(18 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the TEMD Dyslipidemia Study among 4,504 T2D patients, only 8.4% of patients attained target LDL-C levels, and 44.8% of patients were on statin treatment despite the need for statin therapy in 89.5% along with achieving target LDL-C levels by only a quarter of patients on statin therapy (30). Data from TEMD Hypertension Study in 4,756 T2D patients revealed hypertension in 67.5% of patients and 87.4% of hypertensive patients received treatment; BP was on target only in 52.7% of patients (31). Due to the higher rates for glycemic, LDL-C, and BP goal achievement as compared with previous studies in Turkey, authors of the TEMD study emphasized the potential role of an improved healthcare system in Turkey over the years, as well as adherence to regular, follow up in better diabetes care and improved rates for triple target achievement by patients (29).…”

Section: Discussionmentioning

confidence: 99%

Treatment Patterns and Associated Clinical Outcomes in Type 2 Diabetes Patients Initiating Second-Line Glucose-Lowering Therapy: Interim Analysis of Baseline Data from Turkey Arm of the Global DISCOVER Study

Bayram¹,

Sarı²,

Küçükler³

et al. 2021

Turk J Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Treatment Patterns and Associated Clinical Outcomes in Type 2 Diabetes Patients Initiating Second-Line Glucose-Lowering Therapy: Interim Analysis of Baseline Data from Turkey Arm of the Global DISCOVER Study

Bayram¹,

Sarı²,

Küçükler³

et al. 2021

Turk J Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

“…Additionally, the TEMD study results also showed that 90% of people with Type 2 DM were either overweight or obese, while 95% had dyslipidemia followed by HTN in 75% of the patients (9,(14)(15)(16). Unfortunately, the control rate of these comorbidities is very low in Turkey (14)(15)(16). The control rate of glycated hemoglobin (HbA1c), arterial BP (ABP), and low density lipoprotein (LDL) cholesterol all together was only 10% in patients with Type 2 DM and 5% of patients with Type 1 DM (9).…”

Section: Introductionmentioning

confidence: 91%

“…Therefore, all accompanying diseases and their associated risk factors should be controlled efficiently to manage diabetes effectively and prevent any further complications. Additionally, the TEMD study results also showed that 90% of people with Type 2 DM were either overweight or obese, while 95% had dyslipidemia followed by HTN in 75% of the patients (9,(14)(15)(16). Unfortunately, the control rate of these comorbidities is very low in Turkey (14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

Consensus Statement of Endocrinology, Cardiology, and Nephrology (ENCARNE) Experts on Prevention, Diagnosis, and Management of Cardiovascular and Renal Complications of Diabetes

Sönmez¹,

Özdoğan²,

Arıcı³

et al. 2021

Turk J Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

An array of medical practitioners, including endocrinologists, family physicians, internal medicine specialists in nephrology and cardiology, unceasingly investigate, diagnose and treat over 8 million diabetic patients in Turkey. Apart from routine glycemic regulation, several frequent coexisting comorbidities such as obesity, hypertension, dyslipidemia, and their associated complications should also be promptly managed. Due to the concomitant occurrence of complications, the involvement of additional specialties in the precise management of such conditions becomes indispensable. Owing to the ever-expanding knowledge about the prevalence and clinical manifestations of diabetes, various international medical societies publish annual diabetes guidelines, which makes it too cumbersome as well as challenging for the practicing physicians to follow these comprehensive guidelines in clinical practice. There is an unmet need for an easyto-read and concise document for all physicians working for diabetes management for a standardized approach for better management of diabetes and improved patient care. This consensus report was prepared collectively by the Society of Endocrinology and Metabolism Turkey, Turkish Society of Cardiology, Turkish Society of Nephrology, Turkish Society of Hypertension and Renal Diseases to prevent cardiac and renal complications of diabetes, to timely detect these complications by using pertinent measures and to develop, implement and monitor strategies for managing them effectively.

show abstract

“…The 2021 ESC guidelines agree with this recommendation but without target recommendations [ 15 ]. In this context, it should be noted that masked hypertension in which ambulatory or home BP but not office BP readings are in the hypertensive range [ 105 ] is highly prevalent in patients with T2D [ 106 ], making out-of-office BP monitoring a reasonable screening measure for this clinical condition [ 107 ]. Patients with diabetes and hypertension should be examined by ECG at resting state in order to detect silent MI, which occurs in 4 % of all diabetic patients, as insult for HF [ 10 ].…”

Section: Detection Of Heart Failure In Diabetesmentioning

confidence: 99%

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management

Ceriello

Catrinoiu

Chandramouli

et al. 2021

Cardiovasc Diabetol

View full text Add to dashboard Cite

Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes. This review summarizes the proposed mechanistic bases, explaining the myocardial damage induced by diabetes-related stressors and other risk factors, i.e., cardiomyopathy in type 2 diabetes. We highlight the complex pathology of individuals with type 2 diabetes, including the relationship with chronic kidney disease, metabolic alterations, and heart failure. We also discuss the current criteria used for heart failure diagnosis and the gold standard screening tools for individuals with type 2 diabetes. Currently approved pharmacological therapies with primary use in type 2 diabetes and heart failure, and the treatment-guiding role of NT-proBNP are also presented. Finally, the influence of the presence of type 2 diabetes as well as heart failure on COVID-19 severity is briefly discussed.

show abstract

Characteristics of patients with hypertension in a population with type 2 diabetes mellitus. Results from the Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Hypertension Study)

Cited by 19 publications

References 68 publications

Treatment Patterns and Associated Clinical Outcomes in Type 2 Diabetes Patients Initiating Second-Line Glucose-Lowering Therapy: Interim Analysis of Baseline Data from Turkey Arm of the Global DISCOVER Study

Treatment Patterns and Associated Clinical Outcomes in Type 2 Diabetes Patients Initiating Second-Line Glucose-Lowering Therapy: Interim Analysis of Baseline Data from Turkey Arm of the Global DISCOVER Study

Consensus Statement of Endocrinology, Cardiology, and Nephrology (ENCARNE) Experts on Prevention, Diagnosis, and Management of Cardiovascular and Renal Complications of Diabetes

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management

Contact Info

Product

Resources

About